STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who wiII be closely monitored and have regular follow-up. Patients may self-inject with STELARA® after physician approval and proper training. Patients should be instructed to follow the directions provided in the Medication Guide.
*In patients weighing >220 lb. 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these patients.1
Reference: 1. STELARA® (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech, Inc.